 SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 GLOBE NEWSWIRE -- Kinnate Biopharma Inc. Nasdaq: KNTE Kinnate, a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress KN-4802, NCT05242822 evaluating the Companys investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology ASCO-related conferences. 